Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Triple Negative Breast Neoplasms 4Breast Neoplasms 3HR+ Breast Cancer 1HER2+ Breast Cancer 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 402Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 139Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Neoplasms × sintilimab × Breast × Clear all
NCT07254858 2025-11-28

CISN-L

First Affiliated Hospital of Wenzhou Medical University

Phase 2 Not yet recruiting
302 enrolled
Breast

Breast Neoplasms

NCT06308939 2024-03-13

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

Zhejiang Cancer Hospital

Phase 2 Not yet recruiting
81 enrolled
Breast

Breast Neoplasms

NCT05386524 2023-02-16

Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC

Fudan University

Phase 2 Unknown
41 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡